The non-anticoagulant heparin-like K5 polysaccharide derivative K5-N,OSepi attenuates myocardial ischaemia/reperfusion injury

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 9, 2012, Pages 2196-2207

  Collino, Massimo ^a   Pini, Alessandro ^b   Mastroianni, Rosanna ^b   Benetti, Elisa ^a   Lanzi, Cecilia ^b   Bani, Daniele ^b   Chini, Jacopo ^c   Manoni, Marco ^c   Fantozzi, Roberto ^a   Masini, Emanuela ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c INALCO RSM SpA   (Italy)

Author keywords

Apoptosis; Heparin like derivative; Inflammation; K5 N; Myocardial ischaemia reperfusion; OSepi

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; 8-HYDROXY-2'-DEOXYGUANOSINE; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; CALCIUM; CAPSULAR POLYSACCHARIDE K5; CASP3 PROTEIN, RAT; CASPASE 3; DEOXYGUANOSINE; DRUG DERIVATIVE; HEPARIN; PROSTAGLANDIN E2; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; APOPTOSIS; ARTICLE; BACTERIAL CAPSULE; COMPUTER ASSISTED DIAGNOSIS; DRUG EFFECT; HEART MUSCLE; INFLAMMATION; MALE; METABOLISM; METHODOLOGY; PATHOLOGY; RAT; REPERFUSION INJURY; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; APOPTOSIS; BACTERIAL CAPSULES; CALCIUM; CASPASE 3; DEOXYGUANOSINE; DIAGNOSIS, COMPUTER-ASSISTED; DINOPROSTONE; HEPARIN; INFLAMMATION; MALE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; RATS; RATS, WISTAR; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865419448     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01530.x     Document Type: Article

References (52)

1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007; 357: 1121-35.
2. Steffens S, Montecucco F, Mach F. The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb Haemost. 2009; 102: 240-7.
3. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res. 2004; 61: 481-97.
4. Mannaioni PF, Masini E. The release of histamine by free radicals. Free Radic Biol Med. 1988; 5: 177-97.
5. Masini E, Bianchi S, Gambassi F, et al. Ischaemia reperfusion injury and histamine release in isolated and perfused guinea-pig heart: pharmacological interventions. Agents Actions. 1990; 30: 198-201.
6. Hearse DJ, Tosaki A. Free radicals and calcium: simultaneous interacting triggers as determinants of vulnerability to reperfusion-induced arrhythmias in the rat heart. J Mol Cell Cardiol. 1988; 20: 213-23.
7. Kang PM, Izumo S. Apoptosis in heart: basic mechanisms and implications in cardiovascular diseases. Trends Mol Med. 2003; 9: 177-82.
8. Di Napoli P, Taccardi AA, Grilli A, et al. Left ventricular wall stress as a direct correlate of cardiomyocyte apoptosis in patients with severe dilated cardiomyopathy. Am Heart J. 2003; 146: 1105-11.
9. Bialik S, Geenen DL, Sasson IE, et al. Myocyte apoptosis during acute myocardial infarction in the mouse localizes to hypoxic regions but occurs independently of p53. J Clin Invest. 1997; 100: 1363-72.
10. Akasaka Y, Morimoto N, Ishikawa Y, et al. Myocardial apoptosis associated with the expression of proinflammatory cytokines during the course of myocardial infarction. Mod Pathol. 2006; 19: 588-98.
11. Yan AT, Goodman SG. Low-molecular-weight heparins in ischemic heart disease. Curr Opin Cardiol. 2004; 19: 309-16.
12. Friedrichs GS, Kilgore KS, Manley PJ, et al. Effects of heparin and N-acetyl heparin on ischaemia/reperfusion-induced alterations in myocardial function in the rabbit isolated heart. Circ Res. 1994; 75: 701-10.
13. Das P, Ziada K, Steinhubl SR, et al. Heparin-induced thrombocytopenia and cardiovascular diseases. Am Heart J. 2006; 152: 19-26.
14. Pevni D, Frolkis I, Shapira I, et al. Heparin added to cardioplegic solution inhibits tumour necrosis factor-alpha production and attenuates myocardial ischemic-reperfusion injury. Chest. 2005; 128: 1805-11.
15. Rusnati M, Oreste P, Zoppetti G, et al. Biotechnological engineering of heparin/heparan sulphate: a novel area of multi-target drug discovery. Curr Pharm Des. 2005; 11: 2489-99.
16. Gori AM, Attanasio M, Gazzini A, et al. Cytokine gene expression and production by human LPS-stimulated mononuclear cells are inhibited by sulfated heparin-like semi-synthetic derivatives. J Thromb Haemost. 2004; 2: 1657-62.
17. Collino M, Castiglia S, Manoni M, et al. Effects of a semi-synthetic N-, O-sulfated glycosaminoglycan K5 polysaccharide derivative in a rat model of cerebral ischaemia/reperfusion injury. Thromb Haemost. 2009; 102: 837-45.
18. Ceccarelli M, Bani D, Cinci L, et al. Anti-inflammatory effects of low molecular weight heparin derivative in a rat model of carrageenan-induced pleurisy. J Cell Mol Med. 2009; 13: 2704-12.
19. Urbinati C, Bugatti A, Oreste P, et al. Chemically sulfated Escherichia coli K5 polysaccharide derivatives as extracellular HIV-1 Tat protein antagonists. FEBS Lett. 2004; 568: 171-7.
20. Guerrini M, Bisio A, Torri G. Combined quantitative (1)H and (13)C nuclear magnetic resonance spectroscopy for characterization of heparin preparations. Semin Thromb Hemost. 2001; 27: 473-82.
21. Gelvan D, Saltman P, Powell SR. Cardiac reperfusion damage prevented by a nitroxide free radical. Proc Natl Acad Sci USA. 1991; 88: 4680-4.
22. Masini E, Cuzzocrea S, Mazzon E, et al. Protective effects of M40403, a selective superoxide dismutase mimetic, in myocardial ischaemia and reperfusion injury in vivo. Br J Pharmacol. 2002; 136: 905-17.
23. Bani D, Masini E, Bello MG, et al. Relaxin protects against myocardial injury caused by ischaemia and reperfusion in rat heart. Am J Pathol. 1998; 152: 1367-76.
24. Aruoma OI, Halliwell B, Laughton MJ, et al. The mechanism of initiation of lipid peroxidation. Evidence against a requirement for an iron(II)-iron(III) complex. Biochem J. 1989; 258: 617-20.
25. Masini E, Bani D, Vannacci A, et al. Reduction of antigen-induced respiratory abnormalities and airway inflammation in sensitized guinea pigs by a superoxide dismutase mimetic. Free Radic Biol Med. 2005; 39: 520-31.
26. Stennicke HR, Salvesen GS. Biochemical characteristics of caspases-3, -6, -7, and -8. J Biol Chem. 1997; 272: 25719-23.
27. Collino M, Thiemermann C, Mastrocola R, et al. Treatment with the glycogen synthase kinase-3beta inhibitor, TDZD-8, affects transient cerebral ischaemia/reperfusion injury in the rat hippocampus. Shock. 2008; 30: 299-307.
28. Magee KD, Campbell SG, Moher D, et al. Heparin versus placebo for acute coronary syndromes. Cochrane Database Syst Rev. 2008: CD003462.
29. Wang L, Brown JR, Varki A, et al. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest. 2002; 110: 127-36.
30. Thourani VH, Brar SS, Kennedy TP, et al. Nonanticoagulant heparin inhibits NF-kappaB activation and attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol. 2000; 278: H2084-93.
31. 2+ loading during simulated ischaemia and decreases reperfusion injury. Am J Physiol Heart Circ Physiol. 2010; 298: H102-11.
32. Hide EJ, Thiemermann C. Limitation of myocardial infarct size in the rabbit by ischaemic preconditioning is abolished by sodium 5-hydroxydecanoate. Cardiovasc Res. 1996; 31: 941-6.
33. Schultz JE, Hsu AK, Gross GJ. Ischemic preconditioning in the intact rat heart is mediated by delta1- but not mu- or kappa-opioid receptors. Circulation. 1998; 97: 1282-9.
34. Pikas DS, Li JP, Vlodavsky I, et al. Substrate specificity of heparanases from human hepatoma and platelets. J Biol Chem. 1998; 273: 18770-7.
35. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002; 53: 31-47.
36. Silvestro L, Viano I, Macario M, et al. Effects of heparin and its desulfated derivatives on leukocyte-endothelial adhesion. Semin Thromb Hemost. 1994; 20: 254-8.
37. Rossoni G, Manfredi B, De Gennaro Colonna V, et al. Nitric oxide and prostacyclin pathways: an integrated mechanism that limits myocardial infarction progression in anaesthetized rats. Pharmacol Res. 2006; 53: 359-66.
38. Thiemermann C, Thomas GR, Vane JR. Defibrotide reduces infarct size in a rabbit model of experimental myocardial ischaemia and reperfusion. Br J Pharmacol. 1989; 97: 401-8.
39. Jaggi AS, Singh M, Sharma A, et al. Cardioprotective effects of mast cell modulators in ischaemia-reperfusion-induced injury in rats. Methods Find Exp Clin Pharmacol. 2007; 29: 593-600.
40. Frangogiannis NG, Lindsey ML, Michael LH, et al. Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischaemia/reperfusion. Circulation. 1998; 98: 699-710.
41. Sanceau J, Kaisho T, Hirano T, et al. Triggering of the human interleukin-6 gene by interferon-gamma and tumour necrosis factor-alpha in monocytic cells involves cooperation between interferon regulatory factor-1, NF kappa B, and Sp1 transcription factors. J Biol Chem. 1995; 270: 27920-31.
42. Whelan RS, Kaplinskiy V, Kitsis RN. Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol. 2010; 72: 19-44.
43. Chen Z, Chua CC, Ho YS, et al. Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice. Am J Physiol Heart Circ Physiol. 2001; 280: H2313-20.
44. Hochhauser E, Cheporko Y, Yasovich N, et al. Bax deficiency reduces infarct size and improves long-term function after myocardial infarction. Cell Biochem Biophys. 2007; 47: 11-20.
45. Chen M, He H, Zhan S, et al. Bid is cleaved by calpain to an active fragment in vitro and during myocardial ischaemia/reperfusion. J Biol Chem. 2001; 276: 30724-8.
46. Vecsernyes M, Juhasz B, Der P, et al. The administration of alpha-melanocyte-stimulating hormone protects the ischemic/reperfused myocardium. Eur J Pharmacol. 2003; 470: 177-83.
47. Das S, Lekli I, Das M, et al. Cardioprotection with palm oil tocotrienols: comparison of different isomers. Am J Physiol Heart Circ Physiol. 2008; 294: H970-8.
48. Sivarajah A, Collino M, Yasin M, et al. Anti-apoptotic and anti-inflammatory effects of hydrogen sulfide in a rat model of regional myocardial I/R. Shock. 2009; 31: 267-74.
49. Lopez-Neblina F, Toledo AH, Toledo-Pereyra LH. Molecular biology of apoptosis in ischaemia and reperfusion. J Invest Surg. 2005; 18: 335-50.
50. Yan L, Tang Q, Shen D, et al. SOCS-1 inhibits TNF-alpha-induced cardiomyocyte apoptosis via ERK1/2 pathway activation. Inflammation. 2008; 31: 180-8.
51. Bajaj G, Sharma RK. TNF-alpha-mediated cardiomyocyte apoptosis involves caspase-12 and calpain. Biochem Biophys Res Commun. 2006; 345: 1558-64.
52. Haudek SB, Taffet GE, Schneider MD, et al. TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. J Clin Invest. 2007; 117: 2692-701.